Why the study?
Myocarditis with systolic dysfunction is not typically associated with paclitaxel use.
Paclitaxel use can rarely induce myocarditis with systolic dysfunction, which can be diagnosed by cardiac MRI and managed with paclitaxel cessation and standard HFrEF therapy.
Paclitaxel cardiotoxicity should be considered in new systolic dysfunction; this case leaves open incidence and monitoring needs.
Myocarditis with systolic dysfunction is not typically associated with paclitaxel use. Here, we present a case of paclitaxel-induced myocarditis with systolic dysfunction developing after two cycles of carboplatin/paclitaxel in a woman with uterine papillary serous carcinoma and no cardiac risk factors. Myocarditis was diagnosed by cardiac MRI. The management of paclitaxel-induced myocarditis includes intravenous diuresis and initiation of heart failure with reduced ejection fraction guideline-directed medical therapy. Cessation of paclitaxel is also recommended in these patients.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: